MAIA Biotechnology, Inc. (MAIA)
(Delayed Data from AMEX)
$3.33 USD
-0.06 (-1.77%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $3.34 +0.01 (0.30%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MAIA 3.33 -0.06(-1.77%)
Will MAIA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MAIA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MAIA
MAIA Soars 20% on Interim Results From Lung Cancer Study
Bears are Losing Control Over MAIA Biotechnology, Inc. (MAIA), Here's Why It's a 'Buy' Now
MAIA: What are Zacks experts saying now?
Zacks Private Portfolio Services
MAIA Biotechnology, Inc. (MAIA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
MAIA Biotechnology (MAIA) Up on Positive Data From NSCLC Study
Other News for MAIA
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
MAIA reports THIO-101 data from third-line treatment shows ORR of 38%
MAIA Biotechnology Reports Progress in Cancer Drug Development